Preventing Addiction Related Suicide (PARS) (PARS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03166709 |
Recruitment Status :
Completed
First Posted : May 25, 2017
Last Update Posted : July 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Suicide Substance-Related Disorders | Behavioral: Preventing Addiction Related Suicide (PARS) Behavioral: Intensive Outpatient Program standard session | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 907 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Stepped wedge - 15 sites randomly divided into 5 groups which are then randomly ordered into 5 steps. Step 1 is all control. During steps 2-6 one group implements the experimental condition in assigned order until all groups are doing experimental condition. |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Preventing Addiction Related Suicide (PARS) - Controlled Trial of Secondary Suicide Prevention |
Actual Study Start Date : | May 5, 2017 |
Actual Primary Completion Date : | May 28, 2020 |
Actual Study Completion Date : | May 28, 2020 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Treatment As Usual
Intensive Outpatient Program (IOP) addiction treatment
|
Behavioral: Intensive Outpatient Program standard session
Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study. |
Experimental: Experimental
Secondary Prevention Intervention (PARS) plus Treatment as Usual
|
Behavioral: Preventing Addiction Related Suicide (PARS)
PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal |
- PARS Behavior Scale [ Time Frame: Six months ]The PARS Behavior Scale assesses for help-seeking behavior of self and others.
- PARS Suicide Knowledge Scale [ Time Frame: Six months ]The PARS Knowledge Scale assesses factual understanding of warning signs, triggers, and interventions for suicide.
- PARS Attitude Scale [ Time Frame: Six months ]The PARS Attitude Scale evaluates stigma and bias toward suicidal acts or persons, as well as perceptions that suicide is preventable if appropriate action is taken.
- Suicidal Behavior Questionnaire - Revised [ Time Frame: Six months ]The Suicidal Behavior Questionnaire - Revised assesses suicide attempts, ideation, communication, and intent since the last assessment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Enrolled client in one of the community treatment settings
- Over 18 years of age (no maximum age)
- Ability to understand written and spoken English
Exclusion Criteria:
1. Any clinical medical/psychiatric condition, severity of that condition, or life situation that in the opinion of the counselors or Drs. Comtois or Ries would compromise safe and voluntary study participation (e.g., psychosis, custody conflict). This is expected to be a rare circumstance and will be known prior to the recruitment session. If a counselor does not want someone involved, they will not be. If counselor is unsure, Dr. Comtois or Ries will facilitate decision with counselor ahead of time to assist in the decision.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03166709
United States, Washington | |
Lakeside-Milam | |
Auburn, Washington, United States, 98002 | |
Lakeside-Milam | |
Edmonds, Washington, United States, 98026 | |
Evergreen Recovery Centers | |
Everett, Washington, United States, 98201 | |
Lakeside-Milam | |
Everett, Washington, United States, 98204 | |
Olalla Recovery Centers | |
Gig Harbor, Washington, United States, 98335 | |
Lakeside-Milam | |
Issaquah, Washington, United States, 98027 | |
Lakeside-Milam | |
Kirkland, Washington, United States, 98033 | |
Northwest Integrated Health | |
Lakewood, Washington, United States, 98499 | |
Evergreen Recovery Centers | |
Lynnwood, Washington, United States, 98036 | |
Lakeside-Milam | |
Puyallup, Washington, United States, 98371 | |
Northwest Integrated Health | |
Puyallup, Washington, United States, 98374 | |
Lakeside-Milam | |
Renton, Washington, United States, 98055 | |
Lakeside-Milam | |
Seattle, Washington, United States, 98102 | |
THS | |
Seattle, Washington, United States, 98104 | |
Lakeside-Milam | |
Tacoma, Washington, United States, 98405 | |
Northwest Integrated Health | |
Tacoma, Washington, United States, 98406 |
Principal Investigator: | Katherine Anne Comtois, PhD, MPH | University of Washington |
Responsible Party: | Kate Comtois, Professor, Dept of Psychology, University of Washington |
ClinicalTrials.gov Identifier: | NCT03166709 |
Other Study ID Numbers: |
STUDY00001966 1R01DA041486-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | May 25, 2017 Key Record Dates |
Last Update Posted: | July 2, 2020 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Substance-Related Disorders Suicide Self-Injurious Behavior |
Behavioral Symptoms Chemically-Induced Disorders Mental Disorders |